Clinical Trial News and Research

RSS

Dietary adjustments may help control prostate cancer in men undergoing active surveillance

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.

14 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Study links intermittent fasting to slower hair growth

Intermittent fasting has proven benefits for metabolic health, but a new study shows that it could slow hair growth - at least in mice.

13 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Chest wall irradiation does not impact 10-year survival in intermediate-risk breast cancer

Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy, according to results from the BIG 2-04 MRC SUPREMO clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Common brain network connected to heterogeneous patterns of brain atrophy in schizophrenia

A new study led by investigators from Mass General Brigham has identified a unique brain network that links varied patterns of brain atrophy, or shrinkage, associated with schizophrenia.

12 Dec 2024

Controversy surrounds landmark anti-platelet drug trial

An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the US and Brilique in Europe), manufactured by AstraZeneca.

11 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.

11 Dec 2024

Quality breakfast reduces the risk of cardiovascular disease

Having a quality breakfast that provides the right amount of energy to face the day, around a quarter of daily intake, reduces the risk of cardiovascular disease.

11 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Empathy-focused phone calls improve blood sugar control for low-income adults with diabetes

Empathy-focused phone calls made by trained, nonmedical community members led to significant improvements in blood sugar control for low-income adults with diabetes, according to a new study from Dell Medical School at The University of Texas at Austin in collaboration with Lone Star Circle of Care.

10 Dec 2024

Previous
1
...
91
92
93
94
95
96
97
...
1184
Next

Clinical Trial News and Research

Dietary adjustments may help control prostate cancer in men undergoing active surveillance

Promising combination therapy could improve liver cancer outcomes

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

Study links intermittent fasting to slower hair growth

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Chest wall irradiation does not impact 10-year survival in intermediate-risk breast cancer

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Common brain network connected to heterogeneous patterns of brain atrophy in schizophrenia

Controversy surrounds landmark anti-platelet drug trial

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Quality breakfast reduces the risk of cardiovascular disease

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

Empathy-focused phone calls improve blood sugar control for low-income adults with diabetes

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer